

# Online Collaborator Solicitation - TRND

From Altum PCDEMO site, 10-9-2014

Proposal To: NIH - Therapeutics for Rare and Neglected Diseases *NIH - Therapeutics for Rare and Neglected Diseases*  
Title (Applicant): **AMP-086 for the treatment of Pompe Disease (TEST SUBMISSION) (Pilon, Andre)**

Deadline: 9/30/2013 5:00:00 PM (U.S. Eastern Time)

### Proposal Sections

Click name below to go to that section.

- 1) [Title Page](#)
- 2) [Download Templates & Instructions](#)
- 3) [Enable Other Users to Access this Proposal](#)
- 4) [Applicant/PI](#)
- 5) [Institution & Contacts](#)
- 6) [Key Personnel](#)
- 7) [Project Information Category](#)
- 8) [Abstract](#)
- 9) [Proposal Narrative and Other Attachments](#)
- 10) [Validate](#)
- 11) [Print- NO SIGNATURE PAGES REQUIRED FOR TRND](#)

### Support Links

- [Grantmaker Website](#)
- [Program Guidelines](#)
- [Email to Program Admin](#)

### Title Page

The submission deadline for this program has passed and you cannot submit the application.

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The current OMB number is 0925-0658. The expiration date is: 06/30/2015. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0658). Do not return the completed form to this address.

This is not a grant application rather this is an opportunity to collaborate with the TRND Program.

Enter a title for your application, then press Save.  
Press Next to save any changes and go to the next proposal section.

\* Project Title

\* Affiliation

\* Is this a  resubmission

\* Application Type

\* Phase

\* Disease indications  Select Rare or Neglected from the drop-down list. If both, select "Rare and Neglected".

\* How did you hear about TRND?

If you selected Conference or Other, please describe

\* Mechanism of Action

Proposal To: NIH - Therapeutics for Rare and Neglected Diseases *NIH - Therapeutics for Rare and Neglected Diseases*  
Title (Applicant): **AMP-086 for the treatment of Pompe Disease (TEST SUBMISSION) (Pilon, Andre)**

Deadline: **9/30/2013 5:00:00 PM (U.S. Eastern Time)**

### Proposal Sections

Click name below to go to that section.

- 1) [Title Page](#)
- 2) [Download Templates & Instructions](#)
- 3) [Enable Other Users to Access this Proposal](#)
- 4) [Applicant/PI](#)
- 5) [Institution & Contacts](#)
- 6) [Key Personnel](#)
- 7) [Project Information Category](#)
- 8) [Abstract](#)
- 9) [Proposal Narrative and Other Attachments](#)
- 10) [Validate](#)
- 11) [Print- NO SIGNATURE PAGES REQUIRED FOR TRND](#)

[<<Previous](#)[Next>>](#)[Cancel](#)[Exit](#)

**The submission deadline for this program has passed and you cannot submit the application.**

Download	Template Type	Description	File Type	File Size
<a href="#">Download</a>	Instructions for Required Documents	Instructions for Required Documents	.PDF	244283
<a href="#">Download</a>	Proposal	Proposal	.DOCX	62979

Many of the grantmakers in proposalCENTRAL request or require that applicants submit their attachments as portable document format (.pdf). Using PDFs allows you to preserve the formatting of your document. In order to save your documents as PDFs, you will need to use PDF generator software. The National Endowment for Humanities website ([neh.gov](http://neh.gov)) provides a sampling of PDF generators, available for both PCs and Macs, along with websites that will do the conversion for you. Many are free or very low-cost. [Click here for a list of PDF generators.](#)



Proposal To: NIH - Therapeutics for Rare and Neglected Diseases *NIH - Therapeutics for Rare and Neglected Diseases*  
 Title (Applicant): **AMP-086 for the treatment of Pompe Disease (TEST SUBMISSION) (Pilon, Andre)**

Deadline: **9/30/2013 5:00:00 PM (U.S. Eastern Time)**

### Proposal Sections

Click name below to go to that section.

- 1) [Title Page](#)
- 2) [Download Templates & Instructions](#)
- 3) [Enable Other Users to Access this Proposal](#)
- 4) **[Applicant/PI](#)**
- 5) [Institution & Contacts](#)
- 6) [Key Personnel](#)
- 7) [Project Information Category](#)
- 8) [Abstract](#)
- 9) [Proposal Narrative and Other Attachments](#)
- 10) [Validate](#)
- 11) [Print- NO SIGNATURE PAGES REQUIRED FOR TRND](#)

### Support Links

- [Grantmaker Website](#)
- [Program Guidelines](#)
- [Email to Program Admin](#)

### Applicant/PI

[Save](#)
[Print](#)
[<<Previous](#)
[Next>>](#)
[Cancel](#)
[Exit](#)

The submission deadline for this program has passed and you cannot submit the application.

Person who initially creates the proposal is pre-loaded as the PI. Contact information from PI's profile is shown below. To update profile, click Edit Profile. To change PI, select from list and **click button to confirm selection.**

[Instructions](#)

Principal Investigator

[Edit Professional Profile](#)

Name: Prefix \_\_\_\_\_ \* First Andre Middle \_\_\_\_\_ \* Last Pilon

\* Institution National Institutes of Health

Address: MailStop

\* Street 9000 Rockville Pike

\* City Bethesda

State/Province MD \* Zip/Postal Code 20892

\* E-Mail pilona@mail.nih.gov

\* Country United States

Phone: \* Work: 301-827-2746 Fax: 301-827-2534

### Applicant/PI

[Save](#)
[Print](#)
[<<Previous](#)
[Next>>](#)
[Cancel](#)
[Exit](#)

The submission deadline for this program has passed and you cannot submit the application.

# Institution and Contacts

## Proposal Sections

Click name below to go to that section.

- 1) [Title Page](#)
- 2) [Download Templates & Instructions](#)
- 3) [Enable Other Users to Access this Proposal](#)
- 4) [Applicant/PI](#)
- 5) **[Institution & Contacts](#)**
- 6) [Key Personnel](#)
- 7) [Project Information Category](#)
- 8) [Abstract](#)
- 9) [Proposal Narrative and Other Attachments](#)
- 10) [Validate](#)
- 11) [Print- NO SIGNATURE PAGES REQUIRED FOR TRND](#)

## Support Links

- [Grantmaker Website](#)
- [Program Guidelines](#)
- [Email to Program Admin](#)

## Proposal Identifiers

Proposal ID: 66050

Tracking Number:  
Unassigned

## Institution & Contacts

[Save](#)[Print](#)[<<Previous](#)[Next>>](#)[Cancel](#)[Exit](#)

The submission deadline for this program has passed and you cannot submit the application.

PI's institution is pre-loaded as Lead Institution. To change, select from list below or Search all registered institutions. **Press button to confirm selection.** Click Edit Profile button to change institution information.

[Instructions](#)

Lead Institution

**National Institutes of Health**

Click this button to Change the Lead Institution: [Change Institution](#)

Note: Changing institution will delete currently displayed contacts.

### Address

\* **Street** 9000 Rockville Pike  
\* **City** Bethesda  
**State/Province** MD  
\* **Zip/Postal Code** 20892  
\* **Country** United States

If required institution information is missing or appears to be incorrect, please contact the following individual(s). They have access to the institution profile and can make the necessary updates.

Contact	Email	Phone
Piringer, Patricia	ppiringer@nih.gov	301-402-2435

\* **Organization Type**

## Institution & Contacts

[Save](#)[Print](#)[<<Previous](#)[Next>>](#)[Cancel](#)[Exit](#)



Proposal To: NIH - Therapeutics for Rare and Neglected Diseases    *NIH - Therapeutics for Rare and Neglected Diseases*  
 Title (Applicant): **AMP-086 for the treatment of Pompe Disease (TEST SUBMISSION) (Pilon, Andre)**

Deadline: **9/30/2013 5:00:00 PM (U.S. Eastern Time)**

### Proposal Sections

Click name below to go to that section.

- 1) [Title Page](#)
- 2) [Download Templates & Instructions](#)
- 3) [Enable Other Users to Access this Proposal](#)
- 4) [Applicant/PI](#)
- 5) [Institution & Contacts](#)
- 6) [Key Personnel](#)
- 7) [Project Information Category](#)
- 8) [Abstract](#)
- 9) [Proposal Narrative and Other Attachments](#)
- 10) [Validate](#)
- 11) [Print- NO SIGNATURE PAGES REQUIRED FOR TRND](#)

### Key Personnel

[Print](#)   [<<Previous](#)   [Next>>](#)

[Cancel](#)   [Exit](#)

Provide contact information for key personnel, other than the applicant, in the table below.

Role	Name	Title	Institution	Email	Phone	Effort	Action
Key Person	Frosst, Phyllis	Director of Awesomeness	National Institutes of Health	frosstp@mail.nih.gov	301-555-1212		<a href="#">Edit</a> <a href="#">Del</a>
Key Person	Mockname, James	Vice-President of Research	Pfenix Pharmaceuticals	mockname@domain.com	301-555-6869		<a href="#">Edit</a> <a href="#">Del</a>

#### INSTRUCTIONS:

To add a new contact to the table above, enter the e-mail address of the person you wish to add. Click 'Add'. Complete the contact form. (Note: If the person is already registered in proposalCENTRAL, some information will be pre-loaded into the contact form). To edit the person's contact information, click, 'Edit' (in the far right Action column). To delete a person from the table, click 'Del'. (Note: Changes that you make to the person's contact information will be for this proposal only. Permanent changes must be made in the person's Professional Profile). NCI WILL PROVIDE MORE TEXT

Enter email address

Confirm email address

[Add](#)

[Print](#)   [<<Previous](#)   [Next>>](#)

[Cancel](#)   [Exit](#)

Proposal To: NIH - Therapeutics for Rare and Neglected Diseases *NIH - Therapeutics for Rare and Neglected Diseases*Title (Applicant): **AMP-086 for the treatment of Pompe Disease (TEST SUBMISSION)** (Pilon, Andre)Deadline: **9/30/2013 5:00:00 PM (U.S. Eastern Time)**

### Proposal Sections

Click name below to go to that section.

- 1) [Title Page](#)
- 2) [Download Templates & Instructions](#)
- 3) [Enable Other Users to Access this Proposal](#)
- 4) [Applicant/PI](#)
- 5) [Institution & Contacts](#)
- 6) [Key Personnel](#)
- 7) [Project Information Category](#)
- 8) [Abstract](#)
- 9) [Proposal Narrative and Other Attachments](#)
- 10) [Validate](#)
- 11) [Print- NO SIGNATURE PAGES REQUIRED FOR TRND](#)

### Support Links

[Grantmaker Website](#)

### Project Information Category

[Save](#)[Print](#)[<<Previous](#)[Next>>](#)[Cancel](#)[Exit](#)

The submission deadline for this program has passed and you cannot submit the application.

#### Biology/Efficacy:

\* Select the button that describes the stage of your project:

- Identified target(s), likely pharmacological endpoints & functional assays; defined mechanism of action (MOA) of lead compounds; projected the human efficiency dosage and dosing regimen; developed PK/PD relationship
- Demonstrated in-vivo pharmacology in a key animal model (not necessarily by the route of administration)
- Not yet demonstrated in-vivo pharmacology OR in vivo model not yet available or validated
- Not Sure

#### Medicinal Chemistry:

\* Select the button that describes your project stage:

- SAR trends exemplified; no significant physiochemical property concerns
- SAR trends have been identified. Modest challenges still exist, including pharmacologic potency-SAR trends are developing
- SAR trends are unclear OR chemistry complexity interferes with the team's ability to advance the SAR OR multiple active platforms remain to be prioritized
- Not Sure

#### Drug Metabolism and Pharmacokinetics (DMPK) Characterization:



## Project Information – 2(cont.)

### Support Links

[Grantmaker Website](#)

[Program Guidelines](#)

[Email to Program](#)

[Admin](#)

### Proposal Identifiers

Proposal ID: 66050

Tracking Number:

Unassigned

Grantor ID:

Unassigned

### Drug Metabolism and Pharmacokinetics (DMPK) Characterization:

In vivo pharmacokinetic studies and/or in vitro ADME assays (e.g., solubility, permeability, metabolic stability) of lead compounds in this proposal show they have the following DMPK characteristics (select one):

\* Select the button that describes your project:

- High quality DMPK characteristics, thus leads need minimal structure modification  
(e.g., solubility > 60 µg/mL, CL<sub>int</sub> < 0.25 HBF, PK t<sub>1/2</sub> > 8 h or %F > 80%)
- Moderate DMPK characteristics, thus leads need some structure modification  
(e.g., 10 µg/mL < solubility < 60 µg/mL, 0.25 HBF < CL<sub>int</sub> < 0.5 HBF, 1 h < PK t<sub>1/2</sub> < 8 h, or 50% < %F < 80%)
- Poor DMPK characteristics, thus leads need major structure modification  
(e.g., solubility < 10 µg/mL, CL<sub>int</sub> > 0.5 hepatic blood flow (HBF), PK t<sub>1/2</sub> < 1 h, or %F < 20%)
- Unknown DMPK characteristics, because few studies have been performed

### Toxicology

\* Select the button that describes your project:

- Chronic toxicology in two species completed successfully; finished safety pharmacology, mutagenicity, and sub-chronic tox studies
- Conducted acute toxicological studies in rodents; no data generated to date to cause concern
- Literature or experience with this platform indicate that toxicology may be an issue (for peptides, immunogenicity issues have been identified with the lead molecule) OR for pre-lead efforts - in silico & appropriate Tox due diligence not yet complete
- Not Sure

### Chemistry, Manufacturing and Controls (CMC)

Select the button that describes the stage of your project most accurately:

- API scale up – no purification issues, all reactions are

## Project Information – 3(cont.)

### Chemistry, Manufacturing and Controls (CMC)

Select the button that describes the stage of your project most accurately:

- API scale up – no purification issues, all reactions are scalable; Formulation – identified formulation of lead compounds for animal testing and FIH testing; Bioanalytical methods – developed and validated bioanalytical methods
- Have preliminary characterization of API, purity, stability, solvents, for NBE's: chemical composition, glycosylation patterns, payload/protein scaffold ratio, etc.
- Have preliminary formulation and bioanalytical methods for animal studies
- Have not initiated any work on CMC for the lead compounds

### Project Information Category

Save

Print

<<Previous

Next>>

Cancel

Exit

The submission deadline for this program has passed and you cannot submit the application.

# Abstract

## Abstract

[Save](#)[Print](#)[<<Previous](#)[Next>>](#)[Cancel](#)[Exit](#)

The submission deadline for this program has passed and you cannot submit the application.

Please provide a general audience summary below. 4,000 characters max, including spaces.  
Text only. No special characters or formatting. See instructions for details.

[Instructions](#)

\* Kryptonian Syndrome (or Krypto) affects an estimated 5000 patients worldwide. Symptoms become apparent during infancy, with affected children first demonstrating exceptional strength, speed, and agility. Symptoms progress to include an ability to see through walls and levitate above the surface of the Earth. Preliminary evidence suggests that Krypto arises due to the absorption of radiation from the Earth's yellow sun. There are no approved therapies for the treatment of Krypto, other than supportive care. Recently, we have developed a series of compounds that ameliorate the severity of Krypto symptoms in animal models of the disease when administered by slow IV infusion. It is a very effective agent, with good efficacy and toxicity data, but the infusion-related side effects (eg, chills, rigor, fever) have limited the utility of these compounds for chronic administration. We seek support for reformulation of our compounds for oral administration, as well as the appropriate etc. etc. etc.

Select the TRND Resources that apply. You must select at least 1. If resources required are not listed, please list them in the TRND Proposal document.

[Instructions](#)

### \*TRND Resources

07 Evaluate imaging in vitro  
08 Evaluate functional activity in vitro  
09 In vivo efficacy or imaging studies  
10 Develop/validate biomarker assays  
11 Evaluate synthesis & formulation  
12 Evaluate safety issues  
13 Assess potency against efficacy  
14 Evaluate biopharmaceutical properties (bioavailability/ biodistribution/clearance)  
15 For radiopharmaceutical/ animal dosimetry studies  
16 Manufacture GMP-grade bulk drug  
17 Conduct IND-directed toxicology studies  
18 Prepare and review clinical protocol

[>>](#)  
Add

### Selected Categories

[Del](#) 01 For small molecules: secondary assay development  
[Del](#) 02 For small molecules: Medicinal chemistry/SAR  
[Del](#) 03 For small molecules: Compound synthesis/ lab scale  
[Del](#) 04 For biologics: Produce biologic/lab scale  
[Del](#) 05 Compound/biologic profiling (ADMET/potency/ selectivity/ PK/PD & stability)  
[Del](#) 06 Evaluate mechanism of action

[Save](#)[Print](#)[<<Previous](#)[Next>>](#)[Cancel](#)[Exit](#)

The submission deadline for this program has passed and you cannot submit the application.

### Proposal Sections

Click name below to go to that section.

- 1) [Title Page](#)
- 2) [Download Templates & Instructions](#)
- 3) [Enable Other Users to Access this Proposal](#)
- 4) [Applicant/PI](#)
- 5) [Institution & Contacts](#)
- 6) [Key Personnel](#)
- 7) [Project Information Category](#)
- 8) [Abstract](#)
- 9) [Proposal Narrative and Other Attachments](#)
- 10) [Validate](#)
- 11) [Print- NO SIGNATURE PAGES REQUIRED FOR TRND](#)

### Support Links

[Grantmaker Website](#)  
[Program Guidelines](#)  
[Email to Program Admin](#)

### Proposal Identifiers

Proposal ID: 66050

Tracking Number:  
Unassigned

Grantor ID:  
Unassigned

# Proposal Narrative and other Attachments

- Click name below to go to that section.
- 1) [Title Page](#)
  - 2) [Download Templates & Instructions](#)
  - 3) [Enable Other Users to Access this Proposal](#)
  - 4) [Applicant/PI](#)
  - 5) [Institution & Contacts](#)
  - 6) [Key Personnel](#)
  - 7) [Project Information Category](#)
  - 8) [Abstract](#)
  - 9) [Proposal Narrative and Other Attachments](#)
  - 10) [Validate](#)
  - 11) [Print- NO SIGNATURE PAGES REQUIRED FOR TRND](#)
- Support Links**
- [Grantmaker Website](#)
  - [Program Guidelines](#)
  - [Email to Program Admin](#)
- Proposal Identifiers**
- Proposal ID: 66050
- Tracking Number: Unassigned
- Grantor ID: Unassigned

## Attachments

[Print](#) [<<Previous](#) [Next>>](#)

[Cancel](#) [Exit](#)

Download all templates and instructions files located at the bottom portion of this page. Once you have completed each template, click the Browse button in the section directly below, and select the file to attach.

Please note that TRND does not require signatures OR a signature page for submission, this option is for your own optional use only.

Describe Attachment:  (Please provide a meaningful description no longer than 250 characters)

\* Select Appropriate Attachment Type:

Allowable File Type:

\* Select File From Your Computer to attach:  No file selected.

Current list of uploaded attachments are listed in the table below:  
(Files with a highlight cannot be assembled for printing)

Att. Type	Desc.	Ext.	Size	Date	Del	Show
No attachments currently uploaded.						

**Required** attachments that have not been uploaded are listed in the table below. **Optional** attachments that have not been uploaded are not shown.

Allowable File Types	Att. Type	Max.File Size in KB
.PDF	Abstract	10000
.PDF	Biosketch	10000
.PDF	IP Informaton	10000
.PDF	Proposal	10000
.PDF	References	10000

Download available instructions, templates & samples:

Download	Template Type	Description	File Type	File Size
<input type="button" value="Download"/>	Instructions for Required Documents	Instructions for Required Documents	.PDF	244283
<input type="button" value="Download"/>	Proposal	Proposal	.DOCX	62979

Many of the grantmakers in proposalCENTRAL request or require that applicants submit their attachments as portable document format (.pdf). Using PDFs allows you to preserve the formatting of your document. In order to save your documents as PDFs, you will need to use PDF generator software. The National Endowment for Humanities website (neh.gov) provides a sampling of PDF generators, available for both PCs and Macs, along with websites that will do the conversion for you. Many are free or very low-cost. [Click here for a list of PDF generators.](#)

Proposal To: NIH - Therapeutics for Rare and Neglected Diseases    *NIH - Therapeutics for Rare and Neglected Diseases*  
Title (Applicant): **AMP-086 for the treatment of Pompe Disease (TEST SUBMISSION)** (Pilon, Andre)

Deadline: 9/30/2013 5:00:00 PM (U.S. Eastern Time)

### Proposal Sections

Click name below to go to that section.

- 1) [Title Page](#)
- 2) [Download Templates & Instructions](#)
- 3) [Enable Other Users to Access this Proposal](#)
- 4) [Applicant/PI](#)
- 5) [Institution & Contacts](#)
- 6) [Key Personnel](#)
- 7) [Project Information Category](#)
- 8) [Abstract](#)
- 9) [Proposal Narrative and Other Attachments](#)
- 10) [Validate](#)
- 11) [Print- NO SIGNATURE PAGES REQUIRED FOR TRND](#)

### Support Links

- [Grantmaker Website](#)
- [Program Guidelines](#)
- [Email to Program Admin](#)

### Proposal Identifiers

Proposal ID: 66050

Tracking Number:  
Unassigned

Grantor ID:  
Unassigned

### Validate Proposal

[<<Previous](#)   [Next>>](#)

[Cancel](#)   [Exit](#)

Click the 'Validate' button below to check for any missing REQUIRED information or files. All missing required information will be listed on the screen. Please correct any missing information before proceeding to the next step.

**Validate**

Proposal To: NIH - Therapeutics for Rare and Neglected Diseases    *NIH - Therapeutics for Rare and Neglected Diseases*

Title (Applicant): *AMP-086 for the treatment of Pompe Disease (TEST SUBMISSION)* (Pilon, Andre)

Deadline: 9/30/2013 5:00:00 PM (U.S. Eastern Time)

### Proposal Sections

Click name below to go to that section.

- 1) [Title Page](#)
- 2) [Download Templates & Instructions](#)
- 3) [Enable Other Users to Access this Proposal](#)
- 4) [Applicant/PI](#)
- 5) [Institution & Contacts](#)
- 6) [Key Personnel](#)
- 7) [Project Information Category](#)
- 8) [Abstract](#)
- 9) [Proposal Narrative and Other Attachments](#)
- 10) [Validate](#)
- 11) [Print- NO SIGNATURE PAGES REQUIRED FOR TRND](#)

### Support Links

- [Grantmaker Website](#)
- [Program Guidelines](#)
- [Email to Program Admin](#)

### Proposal Identifiers

Proposal ID: 66050

Tracking Number:  
Unassigned

### Print- NO SIGNATURE PAGES REQUIRED FOR TRND

<<Previous

Cancel    Exit

After you complete all the proposal sections, click one of the Print buttons below to open and print the cover/signature pages and application files. *Before printing, please use the "Validate" option (in the gray navigation menu to the left) to verify that you have entered all the required information.*

Print Signature Pages

Print Signature Pages and Attached PDF Files

Click this button to print just the signature pages. Clicking the print button will open the cover/signature pages in PDF format. Data that you entered in the other sections of the proposal are automatically included in the cover/signature pages. If information is missing in the cover/signature pages, it could be because you have not entered the information in one of the proposal sections OR the information is not required for this grant program.

Click this button to print the signature pages plus attached PDF files. (Excludes non-PDF files). Follow the program guidelines for any additional requirements for printing and submitting any other proposal information in the hard-copy submission.

You must have the FREE Adobe Acrobat Reader installed to view either of the above options.

**Attention Apple/Mac users:** The default Apple PDF viewer will not work properly.

Download the latest version of the Acrobat Reader from Adobe at <http://www.adobe.com/products/acrobat/readermain.html>

<<Previous

Cancel    Exit